Raymond James Financial
ACRS icon

Raymond James Financial’s Aclaris Therapeutics ACRS Stock Holding History

Raymond James Financial’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$999K Sell
266,448
-3,236
-1% -$10.9K ﹤0.01% 3839
2025
Q4 		$812K Sell
269,684
-13,792
-5% -$34.8K ﹤0.01% 3922
2025
Q3 		$539K Buy
283,476
+6,217
+2% +$10.8K ﹤0.01% 4081
2025
Q2 		$394K Buy
277,259
+26,454
+11% +$35.8K ﹤0.01% 4141
2025
Q1 		$384K Buy
250,805
+96,454
+62% +$206K ﹤0.01% 4081
2024
Q4 		$383K Buy
+154,351
New +$384K ﹤0.01% 4049

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Raymond James Financial's ACRS Position: Q1 2026 in Review

Raymond James Financial reduced its Aclaris Therapeutics (ACRS) stake by 1.2% in Q1 2026, selling an estimated $10.9K and leaving 266,448 shares worth $999K. The position accounts for ﹤0.01% of the portfolio, ranked #3839.

Raymond James Financial first reported a position in ACRS in Q4 2024 and has held it in 6 quarters since. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Raymond James Financial held 266,448 shares of Aclaris Therapeutics worth $999K as of Q1 2026.
  • Raymond James Financial sold 3,236 Aclaris Therapeutics shares in Q1 2026, an estimated $10.9K.
  • Aclaris Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #3839 holding.
  • Raymond James Financial first reported a position in Aclaris Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.